Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Infinity Pharmaceuticals has commenced two Phase 1 clinical trials of IPI-145, an orally available inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma, which are used in hematologic cancers and inflammatory conditions.
Subscribe to our email newsletter
PI3K delta and gamma are the enzymes involved in immune cell functions, including cell proliferation, survival and cellular trafficking.
The first Phase 1 trial of IPI-145 is a double-blind, randomized, placebo-controlled study which intends to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of IPI-145 in healthy adults.
The second Phase 1 trial is an open-label, dose-escalation study designed to determine the safety, pharmacokinetics and clinical activity of IPI-145 in patients with advanced hematologic malignancies.
After the determination of the maximum tolerated dose in the dose escalation phase, an expansion phase will follow in patients with selected hematologic malignancies.
IPI-145 was licensed from Intellikine and forms part of Infinity’s strategic alliance with Mundipharma International.